Image of Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant orALK-Positive Non–Small-Cell Lung Cancer With Brain Metastases

LITERATURE

Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant orALK-Positive Non–Small-Cell Lung Cancer With Brain Metastases


Patients with advanced EGFR-mutant or ALK-positive non–smallcell lung cancer (NSCLC) have a high cumulative risk (>70%) for developing brainmetastases (BrM) during the course of their disease. Recently, an update of the graded prognostic assessment (GPA) for patients with NSCLCandBrMhas established that molecular alterations in EGFR or ALK are an independent prognostic factor for betteroutcomes.


Availability

REQJ621-02Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
JAMA Oncology
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous